NCT04296266View on ClinicalTrials.gov

Human Salivary Gland Disposition of Alda-341 in Patients Undergoing Salivary Gland Surgery

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

December 18, 2017

Study Completion Date

December 21, 2017

Conditions
Submandibular Gland TumorParotid Gland Tumor
Interventions
DRUG

Alda-341

Dietary supplement d-limonene orally administered as a drug.

Trial Locations (1)

94304

Stanford University, Stanford

All Listed Sponsors
lead

Stanford University

OTHER

NCT04296266 - Human Salivary Gland Disposition of Alda-341 in Patients Undergoing Salivary Gland Surgery | Biotech Hunter | Biotech Hunter